A carregar...
Overcoming mutation-based resistance to antiandrogens with rational drug design
The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospect...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
eLife Sciences Publications, Ltd
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3622181/ https://ncbi.nlm.nih.gov/pubmed/23580326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.00499 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|